Invasive fungal infections refer to severe diseases caused by pathogenic fungi that penetrate and spread within the body beyond the point of initial infection. These infections are characterized by the penetration of fungal organisms into deeper layers of tissue, such as the bloodstream, organs, or other body structures. Invasive fungal infection treatment typically includes using antifungal medications and surgical procedures to excise infected tissue in certain instances.
Sizing and Forecast
The invasive fungal infections market size has grown strongly in recent years. It will grow from $7.21 billion in 2023 to $7.58 billion in 2024 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to global spread of infections, hematopoietic stem cell transplants, aging population, hospital-acquired infections, environmental factors..
The invasive fungal infections market size is expected to see steady growth in the next few years. It will grow to $9.08 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to global health preparedness, public health education, novel antifungal agents, climate change impact, multidisciplinary approaches.. Major trends in the forecast period include advancements in diagnostic technologies, tailored therapeutic approaches, patient-centric care, combination antifungal therapies, collaborations for drug development..
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/invasive-fungal-infections-global-market-report
Segmentation & Regional Insights
The invasive fungal infections market covered in this report is segmented –
1) By Disease Type: Candidaemi And Invasive Candiasis, Intra Abdominal Candiasis, Cryptococcal Meningitis, Esophageal Candidiasis, Histoplasmosis Acute Pulmonary, Other Disease Type
2) By Drug Type: Polyenes, Triazoles, Echinocandins, Flucytosine, Other Drug Type
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users
North America was the largest region in the invasive fungal infections market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the invasive fungal infections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13189&type=smp
Major Driver Impacting Market Growth
The rise in the population suffering from human immunodeficiency virus (HIV) is expected to propel the growth of the invasive fungal infection market going forward. HIV (Human Immunodeficiency Virus) infection is a virus that compromises the immune system’s ability to defend against diseases and illnesses. The rising number of individuals with compromised immune systems, such as HIV (Human Immunodeficiency Virus) or AIDS (acquired immunodeficiency syndrome), increases the susceptibility to invasive fungal infections, creating opportunities for manufacturers to develop and supply specialized and more effective antifungal drugs. For instance, in July 2023, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS), the Switzerland-based United Nations program dedicated to addressing the global HIV/AIDS epidemic, the global population living with HIV increased to 39 million in 2022, up 3.17% from 37.7 million in 2020. Furthermore, there were approximately 1.3 million new HIV infections reported in 2022. Therefore, the rise in the population suffering from the human immunodeficiency virus (HIV) will drive the growth of the invasive fungal infection market.
Key Industry Players
Major companies operating in the invasive fungal infections market report are Pfizer Inc., Merck And Co. Inc., Bayer AG, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Siemens Healthineers, Mylan N.V., Astellas Pharma Inc., Quest Diagnostics Incorporated, Sun Pharmaceutical Industries Ltd., BioMérieux SA, BioMarin Pharmaceutical Inc., Xellia Pharmaceuticals, Basilea Pharmaceutica, Cidara Therapeutic Inc., Pulmocide Ltd., NovaBiotics Ltd, F2G Ltd., Giner Inc., Ciron Drugs And Pharmaceuticals Pvt. Ltd., Hexima Limited, Scynexis Inc., Enzon Pharmaceuticals Inc., Matinas BioPharma Holdings Inc., Biosergen AB
The invasive fungal infections market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
